acute leukemia

WEDNESDAY, Jan. 8, 2025 -- In a new position statement published online Jan. 3 in The Lancet Haematology , guidelines are presented for the management of acute leukemia and aggressive lymphomas in pregnancy. Georgia Mills, M.B.B.S., from Northern Beaches Hospital in Sydney, and colleagues developed a position statement on the diagnosis and management of acute leukemia and aggressive lymphomas in pregnancy, which pose a unique challenge as both maternal and fetal well-being must be considered. The authors note that diagnosis of hematological malignancies can be challenging in pregnancy, but timely diagnosis is required, with either a bone marrow aspirate and trephine or lymph node biopsy, or both. Imaging modalities without ionizing radiation are safe in pregnancy, but effects of radiation should be considered. A multidisciplinary collaborative approach to performing imaging in pregnancy is recommended. Furthermore, a multidisciplinary approach to care is required. To avoid conflicting advice to patients, clear, consistent, multidisciplinary communication between teams is imperative. Unless contraindicated, patients should receive standard-of-care hematological management to optimize both relapse-free and overall survival. Consideration of oncological and pregnancy-based issues and their interactions is important. Key clinical considerations include the natural history of the underlying malignancy, parental wishes and expectations, and physiological changes in pregnancy that may impact pharmacokinetics. Access to nursing and midwifery specialists and comprehensive counseling relating to medication exposures during pregnancy and breastfeeding are recommended. "In providing optimal care, close communication, shared decision-making, and maintaining focus on the goals of a successful pregnancy outcome and a complication-free survival are necessary," the authors write. "Evidence-based and empathic multidisciplinary care is crucial to achieve these aims."

Physician specializes in stem cell transplantation for blood cancers DETROIT, Jan. 7, 2025 /PRNewswire/ -- The Barbara Ann Karmanos Cancer Institute welcomes José Larios, M.D., transplant hematologist. Dr. Larios is a member of the Bone Marrow and Stem Cell Transplant and Hematology Oncology Multidisciplinary Teams at Karmanos. He specializes in treating leukemia and lymphoma blood cancers, including Hodgkin and non-Hodgkin lymphomas. He began seeing patients at the Karmanos Cancer Center in Detroit in August 2024. Continue Reading José Larios, M.D., transplant hematologist, joined the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan. "Karmanos Cancer Institute is an NCI (National Cancer Institute)-Designated Comprehensive Cancer Center known for its expertise in treating solid and hematologic tumors," said Dr. Larios. "During my fellowship training, I was privileged to work with the incredible transplant and hematology teams, under the guidance and mentorship of Dr. Uberti in stem cell transplant and Dr. Yang in malignant hematology. I am now honored to be a part of the hematology and transplant team at the Barbara Ann Karmanos Cancer Institute." Dr. Larios has research and clinical interests in the role of bone marrow microenvironment in leukemia progression. This includes bone marrow signaling in acute leukemias, stem cell transplantation, and cellular therapy. He completed his postdoctoral fellowship in a breast oncology and pharmacology lab at the University of Michigan and investigated molecular mechanisms of endocrine resistance in hormone receptor-positive breast cancer. He recapitulated newly published mutations in the estrogen receptor gene using breast cancer cell lines as pre-clinical models. Additionally, Dr. Larios also examined mechanisms of resistance to CDK4/6 inhibitors. "With Karmanos being an NCI-Designated Comprehensive Cancer Center, in partnership with Wayne State University, Dr. Larios' research and interests will lead to significant discovery in the way we currently treat leukemias and lymphomas with stem cell transplantation," explained George Yoo, M.D., FACS, Chief Medical Officer at Karmanos Cancer Hospital. "Having physicians that push the standard of care needle forward is just what we need in the fight against cancer, to help with future treatments that cure cancers and lead to a better quality of life after treatment." In addition to his postdoctoral fellowship work, Dr. Larios completed an internal medicine residency at Ascension Providence Hospital in Southfield and received his medical degree at Ross University School of Medicine, which was in Dominica at that time. He is board-certified by the American Board of Internal Medicine, where he is also a diplomate in Internal Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the American Medical Association. He serves on the editorial board for the European Journal of Neurology and has co-authored multiple peer-reviewed published studies. View Dr. Lario's physician profile here. To request an appointment, visit karmanos.org or call 1-800-KARMANOS. About the Barbara Ann Karmanos Cancer Institute Karmanos Cancer Institute is a leader in transformative cancer care, research and education through courage, commitment and compassion. The Karmanos vision is a world free of cancer. As part of McLaren Health Care, Karmanos is the largest provider of cancer care and research in Michigan. For more than 75 years, the administrative and research headquarters, along with the premier specialty cancer hospital, have been located in downtown Detroit. With 16 network sites, Karmanos delivers world-renowned care and access to clinical trials throughout Michigan and northern Ohio. The National Cancer Institute recognizes Karmanos as one of the best cancer centers in the nation with a comprehensive cancer center designation. Its academic partnership with the Wayne State University School of Medicine provides the framework for cancer research and education – defining new standards of care and improving survivorship. For more information, call 1-800-KARMANOS (800-527-6266) or visit . Follow Karmanos on Facebook, Twitter, LinkedIn and YouTube. About the Bone Marrow & Stem Cell Transplantation Program at Karmanos The Karmanos Cancer Institute Bone Marrow Transplantation (BMT) Program is one of only a select group nationwide reporting some of the best survival outcomes for related and unrelated stem cell transplantation, according to data released yearly from the Center for International Blood and Marrow Transplant Registry. In addition, the BMT program has received full accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) – the highest level and the most extensive spectrum of accreditation offered by FACT for Bone Marrow Transplant Programs. Members of the BMT Team have vast experience in clinical research focusing on graft-versus-host disease and immunotherapy. To learn more, click here. SOURCE Karmanos Cancer Institute WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Hemogenyx Pharmaceuticals Opens First Clinical Site for HG-CT-1 Phase I TrialPatient Recruitment Begins for CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia in Adults LONDON, UK / ACCESSWIRE / December 30, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of the first clinical site for its lead asset, HG-CT-1, targeting relapsed/refractory (R/R) acute myeloid leukemia (AML) in adults. Recruitment of patients for the trials has begun.This Phase I trial is designed as a dose-escalation study to evaluate the safety profile of HG-CT-1 in adult patients with R/R AML. Key secondary objectives include assessing the therapy's impact on the following clinical outcomes:Efficacy of HG-CT-1 based on AML-specific response criteriaOverall survival (OS) rates among participating subjectsProgression-free survival (PFS) in evaluable subjectsDuration of response (DoR) in those who achieve clinical responses.These objectives are pivotal for assessing the overall clinical impact of HG-CT-1 on patients with R/R AML, a population with few remaining therapeutic options. The commencement of this trial represents a major milestone for Hemogenyx Pharmaceuticals, enabling the Company to advance this promising therapy into clinical testing at one of the world's most prestigious cancer research institutions.Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:" The opening of our first clinical site for the Phase I trial of HG-CT-1 is a milestone in our mission to revolutionize the treatment landscape for relapsed and refractory acute myeloid leukemia. This trial offers hope to patients who currently face limited treatment options by exploring the safety and potential efficacy of HG-CT-1. We are excited to start this pivotal study."About AML and CAR-T TherapyAML, the most common type of acute leukemia in adults, has poor survival rates (a five-year survival rate of less than 30% in adults) and is currently treated using chemotherapy, rather than the potentially more benign and effective forms of therapy being developed by Hemogenyx Pharmaceuticals. The successful development of a new therapy for AML would have a major impact on treatment and survival rates for the disease.CAR-T therapy is a treatment in which a patient's own T-cells, a type of immune cell, are modified to recognize and kill the patient's cancer cells. The procedure involves: isolating T-cells from the patient; modifying the isolated T-cells in a laboratory using a CAR gene construct (which allows the cells to recognize the patient's cancer); amplifying (growing to large numbers) the newly modified cells; and re-introducing the cells back into the patient.Market Abuse Regulation (MAR) DisclosureCertain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.Enquiries:Hemogenyx Pharmaceuticals plchttps://hemogenyx.comDr Vladislav Sandler, Chief Executive Officer & Co-Founder[email protected]Peter Redmond, Director[email protected] SP Angel Corporate Finance LLPTel: +44 (0)20 3470 0470Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital LimitedTel: +44 (0)20 7469 0930Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plcHemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.SOURCE: Hemogenyx Pharmaceuticals PLC